COLO B Coloplast A/S Class B

Coloplast A/S - Announcement no. 14/2022 - Articles of Association

Coloplast A/S - Announcement no. 14/2022 - Articles of Association

Articles of Association for Coloplast A/S as adopted at the Annual General Meeting of Coloplast A/S held today, 1 December 2022 are enclosed.

Our mission

Making life easier for people

with intimate health care needs



Our values

Closeness... to better understand

Passion... to make a difference

Respect and responsibility... to guide us



Our vision

Setting the global standard

for listening and responding

For further information, please contact 

Investors and analysts

Anders Lonning-Skovgaard

Executive Vice President, CFO

Tel.

Aleksandra Dimovska

Director, Investor Relations

Tel. /

Email:

Kristine Husted Munk

Sr. Manager, Investor Relations

Tel. /

Email:







Press and media

Peter Mønster

Sr. Media Relations Manager

Tel.

Email:

Address

Coloplast A/S

Holtedam 1

DK-3050 Humlebaek

Denmark

Company reg. (CVR)

no. 69749917

Website

  

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care, Interventional Urology and Voice & Respiratory Care. We operate globally and employ more than 14,500 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2022-12.

All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Coloplast A/S                                                                                   Investor Relations                                                                                                                                      Comp. reg. (CVR).                          

Holtedam 1                                                                                       Tel.                                                                                                                                    69749917

DK-3050  Humlebaek                                                                     Fax                                                                                         

Denmark                                                                                          

Attachments



EN
01/12/2022

Underlying

COLO BColoplast A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
COLO B COLOPLAST A/S CLASS B
09/03/25 September 3, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
COLO B COLOPLAST A/S CLASS B
09/02/25 September 2, 2025 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast A/S - Coloplast lancerer ny 5-årig strategi ’Impact4’

Coloplast A/S - Coloplast lancerer ny 5-årig strategi ’Impact4’ Den nye 5-årige strategi, Impact4, vil blive lanceret i dag på selskabets Capital Markets Day 2025. Strategien Impact4 sætter kunden i centrum og udstikker samtidig et ambitiøst mål for selskabet – at hjælpe 4 millioner mennesker på lang sigt. Med Impact4 fokuserer vi på fire strategiske prioriteter, der er afgørende for vores succes og værdiskabelse: ’Grow through innovative customer offerings’ ved at sætte standarden for sundhedspleje og ved at skabe et stærkt fokus på kunderne på tværs af alle vores forretningsområder.’Unl...

September 2, 2025 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast A/S - Coloplast presents new 5-year strategy, Impact4

Coloplast A/S - Coloplast presents new 5-year strategy, Impact4 The new 5-year strategy, Impact4, will be presented today at the company’s Capital Markets Day 2025 The Impact4 strategy puts customers at the centre of everything we do and sets an ambitious goal for the company – to help 4 million people in the long-term. With Impact4, we focus on four strategic priorities which are essential to our success and value creation: Grow through innovative customer offerings, by setting the standard of care and driving strong customer centricity across all our business areas.Unlock next level e...

September 2, 2025 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast A/S - Announcement no. 07/2025 - Coloplast fremlægger nye fi...

Coloplast A/S - Announcement no. 07/2025 - Coloplast fremlægger nye finansielle forventninger frem mod 2030 I forbindelse med lanceringen af Coloplasts nye 5-årige strategi, Impact4, offentliggør virksomheden en ny finansiel ambition med en organisk omsætningsvækst på 7-8 % (5-årige CAGR) frem til regnskabsåret 2029/30, en vækst i absolut EBIT* på niveau med eller over omsætningsvæksten i perioden og et afkast af investeret kapital (ROIC) på mere end 20 % i regnskabsåret 2029/30. På sin Capital Markets Day den 2. september 2025 vil Coloplast præsentere en ny 5-årig strategi, Impact4. I fo...

September 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch